Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose urokinase vs conventional therapy in diabetic foot syndrome with critical limb ischemia
2007-005916-15Phase 3Terminated
- Sponsor
- medac GmbH
- Start
- Feb 2008
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of urokinase in diabetic foot ulcer (DFU), chronic limb-threatening ischemia (CLTI), type 2 diabetes mellitus (T2DM) and 1 more (2 arms), sponsored by medac GmbH. Primary endpoint: Major amputation-free survival at 1 year. Started Feb 2008; status: terminated.
02
Drugs
urokinase
03
Conditions
diabetic foot ulcer (DFU)chronic limb-threatening ischemia (CLTI)type 2 diabetes mellitus (T2DM)diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2007-005916-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005916-15.